Branham Law Group, LLP announces its investigation of Chemed Corporation (NYSE: CHE). This investigation focuses on whether company executives and administrators breached their fiduciary obligations by failing to disclose that Chemed engaged in a scheme to fraudulently bill Medicare for hospice services and failed to maintain adequate controls in its hospice enrollments and Medicare billings. It has been reported that a whistleblower complaint has also been filed alleging similar misconduct.Concerned shareholders -- or anyone with additional information about this case -- who would like more information about their rights and potential remedies can contact attorney Trey Branham at (855) 722-5910 or email@example.com.The allegations against Chemed include fraudulent Medicare billings for unqualified hospice care, profiting from unqualified hospice enrollments, and engaging in a premeditated plan to enroll unqualified hospice patients and fraudulently bill Medicare.Moreover, it appears thatthese actions were a result of Chemed’s failure to put in place proper internal controls. Finally, as a result of these actions, it appears that Chemed’s financial statements were significantly, and materially, overstated without a reasonable basis.“These allegations of fraudulent activity and overstated financials have given rise to great concern about damage to the company and its shareholders,” said attorney Trey Branham. The Branham Law Group, LLP has extensive experience in securities and commercial litigation and handled claims of investor fraud, partnership oppression, shareholder derivative suits, and class actions of all types. The Branham Law Group also advises whistleblowers on appropriate courses of action.